This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Murphy Analytics Issues Updated Research Report On Tibet Pharmaceuticals

SHANGRI-LA COUNTY, China, Aug. 22, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the release of an in-depth research report update by Patrick Murphy, CFA, principal of fee-based, third-party research firm Murphy Analytics.

In his report, Mr. Murphy discusses Tibet Pharmaceuticals' business and current portfolio of five traditional Tibetan medicine products, outlines recent developments and states that Tibet is trading at less than cash value.

"Through our strong growth initiatives and portfolio of five SFDA-approved medicines, Tibet Pharmaceuticals is addressing the increasing demand for pharmaceutical and healthcare products in China," said Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "This research report update provides investors with an in-depth analysis of Tibet's particular strengths in the Traditional Chinese Medicine, or TCM, market in China and delivers a comprehensive overview of our recently reported revenue and earnings as we seek to continue to drive growth in 2011."

This research report update provides investors with a current analysis of the growth of the Chinese pharmaceutical market, and delivers a comprehensive overview of Tibet Pharmaceuticals' recently-reported revenue and earnings. Murphy Analytics also explains that despite Tibet Pharmaceuticals' revenue growth, its current valuation multiple is lower than many of its peers.

In his updated report, Mr. Murphy states, "Various benchmark indices, with varying degrees of relevance for TBET operations, are trading at price / earnings multiples ranging from 12.6x to 20.5x.  A smaller sampling of publicly traded stocks generally operating in the Chinese healthcare / pharmaceutical sector is trading at an average P/E multiple of 5.3x, while TBET is trading at less than half the multiple for this sampling and generally in line with peers that are struggling rather than reporting earnings and revenue growth like TBET."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs